72,905 results match your criteria patients rheumatoid


[REMODELING OF THE LEFT VENTRICLE, SUBCLINICAL MANIFESTATIONS OF ATHEROSCLEROSIS IN PATIENTS WITH HYPERTONIC DISEASE WITH RHEUMATOID ARTHRITIS BY THE INFLUENCE OF DIFFERENT TREATMENT SCHEMES].

Authors:
Y Ivashchuk

Georgian Med News 2021 Mar(312):46-52

State Institution "Zaporozhye Medical Academy of Postgraduate Education" of the Ministry of Health of Ukraine.

Objective - to determine the features of the daily profile of blood pressure (BP), blood lipid spectrum, features of left ventricular remodeling in patients with hypertension in combination with RA and to evaluate the effectiveness of using medium doses of rosuvastatin to correct dyslipidemia in this group of patients. 70 patients aged 40-65 years were examined (average - M±m - 54.88±0. Read More

View Article and Full-Text PDF

Risk Factors for Complications and Revision Surgery after Anatomic and Reverse Total Shoulder Arthroplasty.

J Shoulder Elbow Surg 2021 May 5. Epub 2021 May 5.

Exactech, 2320 NW 66(th) Court, Gainesville, FL 32653, USA.

Background: Complications and revisions following anatomic (aTSA) and reverse (rTSA) total shoulder arthroplasty have deleterious effects on patient function and satisfaction. The purpose of this study is to evaluate patient-specific, implant-specific and technique-specific risk factors for intra-operative complications, postoperative complications, and the occurrence of revisions after aTSA and rTSA.

Methods: A total of 2964 aTSA and 5616 rTSA patients were enrolled in an international database of primary shoulder arthroplasty. Read More

View Article and Full-Text PDF

Comparing cost of intravenous infusion and subcutaneous biologics in COVID-19 pandemic care pathways for Rheumatoid Arthritis and Inflammatory Bowel Disease - A brief UK stakeholder survey.

Int J Clin Pract 2021 May 8:e14341. Epub 2021 May 8.

Res Consortium, Andover, Hampshire, UK.

Objectives: One important group of people at higher risk from the SARS-CoV-2(COVID-19) pandemic are those with autoimmune conditions including rheumatoid arthritis/inflammatory bowel disease. To minimise infection risk, many people have been switched from intravenous to subcutaneous biologics including biosimilars.

Design: The survey was designed to understand comparative economic issues related to the intravenous infusion vs subcutaneous biologic administration routes for infliximab. Read More

View Article and Full-Text PDF

Physical activity in patients with rheumatoid arthritis - an agile lifelong behaviour: a qualitative meta-synthesis.

RMD Open 2021 May;7(2)

Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy, Karolinska Institutet, Huddinge, Sweden.

Background: Physical activity (PA) in rheumatoid arthritis (RA) is considered a cornerstone in the treatment. To highlight aspects involved in supporting a positive PA behaviour, it is important to understand the patients' perceptions of the phenomenon.

Objective: The aim of this qualitative meta-synthesis was to explore and synthesise patient perceptions of PA in RA. Read More

View Article and Full-Text PDF

Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.

J Immunother Cancer 2021 May;9(5)

Department of Medical Oncology, Westmead and Blacktown Hospital, New South Wales, New South Wales, Australia

Background: Clinical trials of immunotherapy have excluded patients with pre-existing autoimmune disease. While the safety and efficacy of single agent ipilimumab and anti-PD1 antibodies in patients with autoimmune disease has been examined in retrospective studies, no data are available for combination therapy which has significantly higher toxicity risk. We sought to establish the safety and efficacy of combination immunotherapy for patients with advanced melanoma and pre-existing autoimmune diseases. Read More

View Article and Full-Text PDF

2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis.

Ann Rheum Dis 2021 May 7. Epub 2021 May 7.

National Rheumatoid Arthritis Society, Littlewick Green, UK.

Background: An important but often insufficient aspect of care in people with inflammatory arthritis (IA) is empowering patients to acquire a good understanding of their disease and building their ability to deal effectively with the practical, physical and psychological impacts of it. Self-management skills can be helpful in this regard.

Objectives: To develop recommendations for the implementation of self-management strategies in IA. Read More

View Article and Full-Text PDF

Elderly patients with comorbidities in the definition of difficult-to-treat rheumatoid arthritis.

Ann Rheum Dis 2021 May 7. Epub 2021 May 7.

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan

View Article and Full-Text PDF

Multiple intravenous tranexamic acid doses in total knee arthroplasty in patients with rheumatoid arthritis: a randomized controlled study.

BMC Musculoskelet Disord 2021 May 7;22(1):425. Epub 2021 May 7.

Shanghai University of Traditional Chinese Medicine, Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, 200052, CN, China.

Background: We aimed to determine the efficacy and safety of multiple doses of intravenous tranexamic acid (IV-TXA) on perioperative blood loss in patients with rheumatoid arthritis (RA) who had undergone primary unilateral total knee arthroplasty (TKA).

Methods: For this single-center, single-blind randomized controlled clinical trial, 10 male and 87 female participants with RA, aged 50-75 years, who underwent unilateral primary TKA were recruited. The patients received one dose of 1 g IV-TXA 10 min before skin incision, followed by articular injection of 1. Read More

View Article and Full-Text PDF

Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort.

Rheumatology (Oxford) 2021 May 7. Epub 2021 May 7.

Statistiques, University Institute of Clinical Research, Montpellier, France.

Objective: To report the 10-year outcome of an inception cohort of patients with early rheumatoid arthritis (RA), the ESPOIR cohort, and predictors of outcome.

Methods: From 2003 to 2005, 813 patients were included if they had early arthritis (< 6 months) with a high probability of RA and had never been prescribed DMARDs. Multivariate analysis was used to evaluate predictors of outcome. Read More

View Article and Full-Text PDF

Burden of Herpes Zoster in Adult Patients with Underlying Conditions: Analysis of German Claims Data, 2007-2018.

Dermatol Ther (Heidelb) 2021 May 6. Epub 2021 May 6.

Department for Health Economics and Health Care Management, Bielefeld University, Universitätsstrasse 25, 33615, Bielefeld, Germany.

Introduction: Several chronic underlying conditions (UCs) are known to be risk factors for developing herpes zoster (HZ) and to increase the severity of HZ and its risk of recurrence. The aim of this study was to investigate the incidence and recurrence of HZ in adult patients with one or multiple UCs.

Methods: A retrospective cohort study based on claims data representing 13% of the statutory health insurance population from 2007 to 2018 in Germany was performed. Read More

View Article and Full-Text PDF

Opposing Trends in Total Knee and Hip Arthroplasties for Patients With Rheumatoid Arthritis vs. the General Population-A 14-Year Retrospective Study in Taiwan.

Front Med (Lausanne) 2021 20;8:640275. Epub 2021 Apr 20.

Department of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan.

To determine the trend of incidence rate of total knee arthroplasty (TKA), total hip arthroplasty (THA), and TKA or THA (major joint arthroplasty, MJA) among rheumatoid arthritis (RA) population and compared them with general population (GP) in Taiwan. Incidence rates and trends of TKA, THA, and MJA were determined over a 14-year period (2000-2013) among RA patients and compared them with GP. RA of patients was diagnosed based on the ACR 1987 criteria and extracted from GP. Read More

View Article and Full-Text PDF

Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study.

Ther Adv Musculoskelet Dis 2021 20;13:1759720X211006964. Epub 2021 Apr 20.

Department of Rheumatology and Immunity, Center of Clinical Immunology, Peking University People's Hospital, Xicheng District, Beijing, P.R. China.

Introduction: To assess the effect of baricitinib on patient-reported outcomes (PROs) in patients with moderately to severely active rheumatoid arthritis (RA) who had an inadequate response to methotrexate (MTX).

Methods: This was a 52-week, randomized, double-blind, placebo controlled, phase III study in patients with RA who had an inadequate response to MTX. Patients ( = 290) receiving stable background MTX were randomly assigned (1:1) to receive placebo or baricitinib 4 mg once daily with a primary endpoint at week 12. Read More

View Article and Full-Text PDF

Tofacitinib versus tocilizumab in the treatment of biological-naïve or previous biological-failure patients with methotrexate-refractory active rheumatoid arthritis.

RMD Open 2021 May;7(2)

Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Sasebo, Japan.

Objectives: To compare effectiveness between tofacitinib and tocilizumab treatments for biological disease-modifying antirheumatic drug (bDMARD)-naïve patients or previous bDMARD-failure patients with active rheumatoid arthritis (RA) refractory to methotrexate (MTX).

Methods: We used two ongoing real-world registries of patients with RA who had first started tofacitinib or tocilizumab between August 2013 and February 2019 at our institutions. Clinical disease activity index (CDAI)-based improvements at 12 months were used for comparisons between tofacitinib and tocilizumab treatments, separately for bDMARD-naïve and previous bDMARD-failure patients. Read More

View Article and Full-Text PDF

Identification of neutrophil β2-integrin LFA-1 as a potential mechanistic biomarker in ANCA-associated vasculitis via microarray and validation analyses.

Arthritis Res Ther 2021 May 6;23(1):136. Epub 2021 May 6.

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan.

Background: Leukocyte activation by anti-neutrophil cytoplasmic antibody (ANCA) and the subsequent leukocyte-endothelium interaction play a key role in the development of endothelial damage in ANCA-associated vasculitis (AAV). In contrast to that of leukocyte activation, the exact role of the leukocyte-endothelium interaction via integrin remains unclear. Here, we performed microarray and validation analyses to explore association between the expression levels of lymphocyte function-associated antigen-1 (LFA-1) and the clinical characteristics of patients with AAV. Read More

View Article and Full-Text PDF

Health care costs of rheumatoid arthritis: A longitudinal population study.

PLoS One 2021 6;16(5):e0251334. Epub 2021 May 6.

University of Toronto, Toronto, Ontario, Canada.

Quantifying the contribution of rheumatoid arthritis to the acquisition of subsequent health care costs is an emerging focus of the rheumatologic community and payers of health care. Our objective was to determine the healthcare costs before and after diagnosis of rheumatoid arthritis (RA) from the public payer's perspective. The study design was a longitudinal observational administrative data-based cohort with RA cases from Ontario Canada (n = 104,933) and two control groups, matched 1:1 on year of cohort entry from 2001 to 2016. Read More

View Article and Full-Text PDF

Medium-Term Clinical Results of High-Flexion Knee Prostheses in Patients with Rheumatoid Arthritis.

Orthop Surg 2021 May 6. Epub 2021 May 6.

Department of Orthopaedics, Xijing Hospital, Air Force Military Medical University, Changle West Road, Xi'an, China.

Objective: This study was performed to evaluate the function and satisfaction outcome of patients with rheumatoid arthritis (RA) who underwent total knee arthroplasty (TKA) with high-flexion prostheses.

Materials And Methods: Twenty-two patients (35 knees) using high-flexion prostheses (Zimmer, Warsaw, IN) were followed up for a period of 7-11 years from February 2007 to December 2009. Clinical and radiographic follow-up was performed using Hospital for Special Surgery (HSS), Short-Form 36 scores (SF-36), American Knee Society score (KSS), and Knee Society Total Knee Arthroplasty Roentgenographic Evaluation and Scoring System. Read More

View Article and Full-Text PDF

GO-BEYOND: a real-world study of persistence of golimumab in patients with axial spondyloarthritis and rheumatoid arthritis in Turkey.

Immunotherapy 2021 May 6. Epub 2021 May 6.

MSD Turkey, Istanbul, Turkey.

To evaluate the retention rate of golimumab (GLM) in patients with rheumatoid arthritis (RA) and axial spondyloarthritis (ax-SpA). Patients had received/were receiving GLM as their first or second biological drug for at least 3 months. We recorded demographic and clinical data, data on drug continuation and disease activity. Read More

View Article and Full-Text PDF

Risk of COVID-19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in At-Risk Individuals.

Arthritis Rheumatol 2021 May 5. Epub 2021 May 5.

Medicine & Research Service, VA Nebraska-Western Iowa Health Care System, Omaha, NE, USA.

Background: While rheumatoid arthritis (RA) and its treatments are associated with an increased infection risk, it remains unclear whether these factors impact the risk or severity of COVID-19.

Methods: We conducted a matched cohort study using national Veterans Affairs data. Among non-deceased individuals on January 1, 2020 who received VA care in 2019, we matched RA to non-RA patients (1:1) on age, sex, and VA site. Read More

View Article and Full-Text PDF

Aggregation of autoimmunity in extended families of people with autoimmune Addison's disease.

Intern Med J 2021 May 5. Epub 2021 May 5.

Department of Endocrinology, Metabolism and Internal Medicine, Poznań University of Medical Sciences, 49 Przybyszewskiego, 60-355, Poznań, Poland.

Background: Autoimmunity accounts for 90% of cases of primary adrenal insufficiency (Addison's disease, AD). Affected persons present a significant co-occurrence of autoimmune conditions, hence, clustering of autoimmunity is also predicted among their relatives.

Aims: The aim of our study was to evaluate the burden of autoimmunity in families of people with AD. Read More

View Article and Full-Text PDF

Cytokines in gingival crevicular fluid in elderly rheumatoid arthritis patients in a population-based cross-sectional study: RANTES was associated with periodontitis.

J Periodontal Res 2021 May 5. Epub 2021 May 5.

Department of Health, Blekinge Institute of Technology, Karlskrona, Sweden.

Objective: We studied cytokines in gingival crevicular fluid (GCF) in a cross-sectional population-based cohort of rheumatoid arthritis (RA) patients ≥61 years of age with and without a diagnosis of periodontitis.

Background Data: Earlier studies on cytokines in GCF in RA patients have not given clear results.

Methods: In a population-based cross-sectional study of patients ≥61 years of age, 233 RA patients were identified. Read More

View Article and Full-Text PDF

Uridine Diphosphate Promotes Rheumatoid Arthritis Through P2Y6 Activation.

Front Pharmacol 2021 19;12:658511. Epub 2021 Apr 19.

Medical Research Center of the Affiliated Hospital of Qingdao University, Qingdao, China.

Uridine diphosphate (UDP) is an extracellular nucleotide signaling molecule implicated in diverse biological processes via specific activation of pyrimidinergic receptor P2Y, G Protein-Coupled, 6 (P2Y6). There is very little knowledge about the function and mechanism of UDP in rheumatoid arthritis (RA). This study used a quasi-targeted liquid chromatography-mass spectrometry (LC-MS) approach to investigate the unique expression of metabolites in RA synovial fluids (SF) ( = 10) with samples from osteoarthritis (OA) as controls ( = 10). Read More

View Article and Full-Text PDF

Improvement of HbA1c in Patients with Type 2 Diabetes Mellitus and Rheumatoid Arthritis Treated with bDMARDs.

Open Access Rheumatol 2021 28;13:73-78. Epub 2021 Apr 28.

Internal Medicine Unit, Legnano Hospital, Milan, Italy.

Objective: The aim of our study was to evaluate the possible role of biological treatments for rheumatoid arthritis (RA) in improving the glycemic profile in patients affected not only by RA but also by type 2 diabetes mellitus (2TDM).

Methods: An observational retrospective study was conducted using data from patients referred to our Rheumatology Unit. Patients with active RA despite standard DMARDs therapy and concomitant 2TDM were selected into one of five exposure groups to first-line bDMARDs (adalimumab, golimumab, etanercept, tocilizumab, sarilumab) and observed for the outcome of CRP, ESR, DAS28CRP and glycated hemoglobin (HbA1c) variations. Read More

View Article and Full-Text PDF

Bone Histomorphometry of Femoral Head Cancellous Bone in Patients Who Underwent Total Hip Arthroplasties due to Destructive Hip in Rheumatoid Arthritis.

Acta Med Okayama 2021 Apr;75(2):125-131

Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences.

Rheumatoid arthritis (RA) affects the hip joints. The microarchitecture of the cancellous bone in RA-affected hip joints has been unclear. Here we investigated the bone metabolism changes in the subcapital cancellous bone of destructive hips of RA patients (n=26 patients; 28 hip joints) which were classified by Larsen grade on X-ray into the groups: destructive hip (Des) (Larsen grade IV, n=18) and neck fracture (Fx) (Larsen grade 0 or 1, n=10). Read More

View Article and Full-Text PDF

Angiotensin II upregulates RANKL/NFATC1 expression in synovial cells from patients with rheumatoid arthritis through the ERK1/2 and JNK pathways.

J Orthop Surg Res 2021 May 5;16(1):297. Epub 2021 May 5.

Department of Joint Surgery, The Affiliated Hospital of Qingdao University, Qingdao, 266000, Shandong, China.

Background: Angiotensin II (Ang II) is associated with rheumatoid arthritis (RA) development. The present study investigated the impact of Ang II on the expression of receptor activator of nuclear factor-κB ligand (RANKL), as well as of nuclear factor of activated T cells cytoplasmic 1 (NFATC1) in RA synovial cells, and explored the underlying mechanism.

Methods: The expression levels of RANKL, NFATC1, and Ang II type 1 receptor (AT1R) were analyzed by RT PCR, western-blot, and/or immunohistochemistry. Read More

View Article and Full-Text PDF

Rheumatoid Arthritis and Associated-Interstitial Lung Disease: Mortality Rates and Trends.

Ann Am Thorac Soc 2021 May 5. Epub 2021 May 5.

Loma Linda University Health, 23331, Loma Linda, California, United States.

Rationale: The burden of rheumatoid arthritis (RA) and RA-associated interstitial lung disease (RA-ILD) in recent years has not been well characterized.

Objective: In this study, we sought to describe RA and RA-ILD-related mortality rates and trends in the U.S. Read More

View Article and Full-Text PDF

The efficacy and safety of silver needle in the treatment of rheumatoid arthritis: A protocol of randomized controlled trial.

Medicine (Baltimore) 2021 May;100(18):e25556

Bayannur City Hospital, Inner Mongolia 015000, China.

Background: Rheumatoid arthritis is a kind of chronic crippling disease, the condition is complex, the course of the disease is repeated, seriously affecting the quality of life of patients. Adverse reactions and drug resistance associated with conventional treatment can no longer meet the clinical need. Therefore, complementary and alternative therapies need to be explored. Read More

View Article and Full-Text PDF

Association between interleukin-1 alpha rs1800587 polymorphism and rheumatoid arthritis: A meta-analysis.

Authors:
Huaguo Wang Yi Wang

Sci Prog 2021 Apr-Jun;104(2):368504211013647

Department of Clinical Laboratory, Wenzhou integrated traditional Chinese and Western Medicine Hospital, Wenzhou, China.

No consistent results have been reached on the relationship of interleukin-1 (IL-1) rs1800587 polymorphism with the susceptibility to rheumatoid arthritis (RA) so far. Therefore, the current meta-analysis was designed to thoroughly review relevant studies, in order to examine the relationship of IL-1A rs1800587 polymorphism with RA risk. Electronic databases were retrieved for literature regarding the relationship between IL-1A rs1800587 polymorphism and RA vulnerability according to the inclusion and exclusion criteria. Read More

View Article and Full-Text PDF

Clinical use of Jak 1 inhibitors for rheumatoid arthritis.

Authors:
Peter Nash

Rheumatology (Oxford) 2021 May;60(Supplement_2):ii31-ii38

School of Medicine, Griffith University, Brisbane, Queensland, Australia.

The uptake of Jak inhibitors in the RA space has been among the most rapid in rheumatology, based on the results of comprehensive clinical trial programmes of five agents. Newer generations of Jak inhibitors, like upadacitinib and filgotinib, target Jak 1 selectively with the aim of maximizing efficacy and to improve safety. This article will review the clinical significance of evidence on: (i) Jak 1 selectivity; (ii) efficacy from the SELECT and FINCH clinical trial programmes including patient intolerant or inadequately responding to MTX (MTX-IR) and other csDMARDs patients who are bDMARD-IR) and those using monotherapy when MTX is not tolerated or contraindicated and those treated when methotrexate naive; and (iii) safety from the clinical trial programmes of these two agents will be discussed. Read More

View Article and Full-Text PDF

Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis.

Rheumatology (Oxford) 2021 May;60(Supplement_2):ii11-ii16

Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin, Berlin, Germany.

The first approved Janus kinase (JAK) inhibitors for treatment of RA targeted more than one JAK molecule. Although this brings an advantage of simultaneous blocking of more cytokines involved in RA, it may also carry an increased risk of toxicity. Subsequently, more selective JAK inhibitors were developed with the aim of improving the safety-efficacy profile and to further increase drug maintenance. Read More

View Article and Full-Text PDF